{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:19:42Z","timestamp":1769156382310,"version":"3.49.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.reuma.2012.02.006","type":"journal-article","created":{"date-parts":[[2013,11,8]],"date-time":"2013-11-08T18:46:42Z","timestamp":1383936402000},"page":"270-277","source":"Crossref","is-referenced-by-count":34,"title":["Raynaud, \u00falceras digitales y calcinosis en esclerodermia"],"prefix":"10.1016","volume":"8","author":[{"given":"Alejandro","family":"Nitsche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2012.02.006_bib0005","first-page":"2423","article-title":"Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study","volume":"34","author":"Hachulla","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2012.02.006_bib0010","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMcp013013","article-title":"Clinical practice. Raynaud's Phenomenon","volume":"347","author":"Wigley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reuma.2012.02.006_bib0015","unstructured":"Sormani de Fonseca ML. Manual de capilaroscop\u00eda .Talleres Gr\u00e1ficos Alfa. Buenos Aires. Edici\u00f3n 2000."},{"key":"10.1016\/j.reuma.2012.02.006_bib0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/0003-4819-137-1-200207020-00007","article-title":"Reporting the recruitment process in clinical trials: who are these patients and how did they get there?","volume":"137","author":"Gross","year":"2002","journal-title":"Ann Inter Med"},{"key":"10.1016\/j.reuma.2012.02.006_bib0025","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/art.23567","article-title":"Canadian Scleroderma Research Group. Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment","volume":"59","author":"Villela","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2012.02.006_bib0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/BOR.0b013e32834aa40b","article-title":"Contemporary management of Raynaud s phenomenon and digital ischaemic complications","volume":"23","author":"Herrick","year":"2011","journal-title":"Curr Opin Rheumatol"},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2012.02.006_bib0035","first-page":"484","article-title":"Treatment on healing and prevention of digital ulcers in systemic sclerosis (SSC): Results from a meta-analysis","volume":"70","author":"Tingey","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2012.02.006_bib0040","first-page":"19","article-title":"Digital ulcers: overt vascular disease in systemic sclerosis","volume":"4","author":"Steen","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reuma.2012.02.006_bib0045","first-page":"3","article-title":"\u00dalceras digitales en esclerosis sist\u00e9mica","volume":"9","author":"Beltr\u00e1n Catal\u00e1n","year":"2008","journal-title":"Sem Fun Esp Reumatol"},{"key":"10.1016\/j.reuma.2012.02.006_bib0050","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Mechanisms of disease. Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reuma.2012.02.006_bib0055","first-page":"308","article-title":"Sistema endotelina","volume":"18","author":"Baltazares Lipp","year":"2005","journal-title":"Rev Inst Nal Enf Resp Mex"},{"key":"10.1016\/j.reuma.2012.02.006_bib0060","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0735-1097(01)01210-4","article-title":"Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?","volume":"37","author":"Spieker","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.reuma.2012.02.006_bib0065","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1161\/01.CIR.102.19.2434","article-title":"Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs","volume":"102","author":"L\u00fcscher","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.reuma.2012.02.006_bib0070","first-page":"1566","article-title":"Significance of plasma endothelin-1 levels in patients with systemic sclerosis","volume":"19","author":"Yamane","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2012.02.006_bib0075","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1136\/hrt.2005.069484","article-title":"Systemic sclerosis associated pulmonary hypertension: improved survival in the current era","volume":"92","author":"Williams","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.reuma.2012.02.006_bib0080","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/rheumatology\/keq097","article-title":"Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 lesions","volume":"49","author":"Amanzi","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.reuma.2012.02.006_bib0085","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2012.02.006_bib0090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","article-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial","volume":"70","author":"Matucci-Cerinic","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2012.02.006_bib0095","first-page":"660","article-title":"Systemic sclerosis: outcome and long term follow-up of 429 pactients from a single Italian centre","volume":"70","author":"Doveri","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2012.02.006_bib0100","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.semarthrit.2005.01.016","article-title":"Calcinosis in rheumatic diseases","volume":"34","author":"Boulman","year":"2005","journal-title":"Semin Artritis Rheum"},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2012.02.006_bib0105","first-page":"475","article-title":"Transition from early to late pattern of nailfold microangiopathy in systemic sclerosis: a quick event to be strictly monitored","volume":"70","author":"Sulli","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2012.02.006_bib0110","first-page":"23","article-title":"Scoring the capillaroscopic images: which hallmark parameters should be scored","volume":"70","author":"Sulli","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2012.02.006_bib0115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/annrheumdis-2011-200022","article-title":"Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study","volume":"71","author":"Sebastiani","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2012.02.006_bib0120","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/ard.2010.136929","article-title":"Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group","volume":"70","author":"Avouac","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2012.02.006_bib0125","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2012.02.006_bib0130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0014-2565(09)70354-6","article-title":"Tratamiento del fen\u00f3meno de Raynaud","volume":"209","author":"Fonollosa-Pla","year":"2009","journal-title":"Revista Cl\u00ednica Espa\u00f1ola"},{"key":"10.1016\/j.reuma.2012.02.006_bib0135","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3899\/jrheum.100358","article-title":"Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension","volume":"37","author":"Rosato","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2012.02.006_bib0140","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2133.2011.10581.x","article-title":"Effects of bosentan on non digital ulcers in patients with systemic sclerosis","volume":"166","author":"Taniguchi","year":"2012","journal-title":"British J Dermatol"},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2012.02.006_bib0145","doi-asserted-by":"crossref","first-page":"iii45","DOI":"10.1093\/rheumatology\/kel290","article-title":"Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan","volume":"45","author":"Selenko-Gebauer","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reuma.2012.02.006_bib0150","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1136\/ard.2007.073684","article-title":"Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis","volume":"66","author":"Hettema","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2012.02.006_bib0155","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/rheumatology\/keh340","article-title":"Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis","volume":"43","author":"Ramos-Casals","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reuma.2012.02.006_bib0160","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/rheumatology\/kei129","article-title":"Treatment of severe Raynaud's phenomenon with bosentan in a patient with systemic sclerosis","volume":"45","author":"Dunne","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl II","key":"10.1016\/j.reuma.2012.02.006_bib0165","first-page":"90","article-title":"Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis","volume":"65","author":"Seibold","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2012.02.006_bib0170","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/rheumatology\/ken001","article-title":"Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients","volume":"47","author":"Garc\u00eda de la Pe\u00f1a-Lefebvre","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"4 Pt 1","key":"10.1016\/j.reuma.2012.02.006_bib0175","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0755-4982(06)74645-0","article-title":"Bosentan for treatment of active digital ulcers in patients with systemic sclerosis","volume":"35","author":"Launay","year":"2006","journal-title":"Presse Med"},{"key":"10.1016\/j.reuma.2012.02.006_bib0180","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/rheumatology\/kel383","article-title":"Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon","volume":"46","author":"Moore","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reuma.2012.02.006_bib0185","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/art.22634","article-title":"Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis","volume":"56","author":"Sfikakis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2012.02.006_bib0190","first-page":"499","article-title":"Long term low molecular weight heparin therapy for severe Raynaud s phenomenon: a pilot study","volume":"18","author":"Denton","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reuma.2012.02.006_bib0195","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.3899\/jrheum.101266","article-title":"Bosentan in clinical practice for treating digital and other ischemic ulcers in spanish patients with systemic sclerosis: IBER-DU cohort study","volume":"38","author":"Roman Ivorra","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2012.02.006_bib0200","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/rheumatology\/keq077","article-title":"Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial","volume":"49","author":"Kuhn","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reuma.2012.02.006_bib0205","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00296-008-0789-z","article-title":"Effects of bosentan on the skin lesions: an observational study from a single center in Japan","volume":"29","author":"Funauchi","year":"2009","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reuma.2012.02.006_bib0210","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/rheumatology\/keh390","article-title":"Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis","volume":"44","author":"Thompson","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reuma.2012.02.006_bib0215","first-page":"CD006687","article-title":"Oral vasodilators for primary Raynaud's phenomenon","volume":"16","author":"Vinjar","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.reuma.2012.02.006_bib0220","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2012.02.006_bib0225","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0140-6736(82)90215-X","article-title":"Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease","volume":"1","author":"Franks","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.reuma.2012.02.006_bib0230","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/rheumatology\/34.7.636","article-title":"Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon","volume":"34","author":"Teh","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.reuma.2012.02.006_bib0235","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archinte.166.2.231","article-title":"Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease","volume":"166","author":"Caglayan","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.reuma.2012.02.006_bib0240","first-page":"1918","article-title":"Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment","volume":"33","author":"Kumar","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2012.02.006_bib0245","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/ard.2009.116475","article-title":"Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study","volume":"69","author":"Brueckner","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2012.02.006_bib0250","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1517\/13543780802525100","article-title":"Phosphodiesrerase-5 inhibitors for the treatment of Raynauds: a novel indication","volume":"18","author":"De LaVega","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.reuma.2012.02.006_bib0255","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1157\/13060173","article-title":"Iloprost for severe Raynaud's phenomenon and ischaemic ulcers related with systemic diseases","volume":"122","author":"Garc\u00eda Hern\u00e1ndez","year":"2004","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.reuma.2012.02.006_bib0260","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1191\/1358863x05vm579cr","article-title":"Treprostinil for the treatment of severe digital necrosis in systemic sclerosis","volume":"10","author":"Engel","year":"2005","journal-title":"Vascular Medicine"},{"issue":"Suppl III","key":"10.1016\/j.reuma.2012.02.006_bib0265","first-page":"S304","article-title":"Treatment of severe Raynaud's phenomenon in collagen diseases with alprostadil IV","volume":"64","author":"Beltr\u00e1n","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2012.02.006_bib0270","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.amjcard.2003.08.013","article-title":"Effects of cilostazol in patients with Raynauds syndrome","volume":"92","author":"Rajagopalan","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.reuma.2012.02.006_bib0275","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/rheumatology\/keg137","article-title":"Serotonin reuptake inhibitors, Raynaud's phenomenon and erythromelalgia","volume":"42","author":"Rey","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.reuma.2012.02.006_bib0280","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1017\/S1461145704004882","article-title":"Treatment of Raynaud's phenomenon with escitalopram","volume":"8","author":"Buecking","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.reuma.2012.02.006_bib0285","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.reuma.2012.02.006_bib0290","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1177\/000331979604700909","article-title":"Digital infarction in a patient with Raynaud's phenomenon associated with treatment with a specific serotonin reuptake inhibitor. A case report","volume":"47","author":"Bell","year":"1996","journal-title":"Angiology"},{"key":"10.1016\/j.reuma.2012.02.006_bib0295","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00296-006-0254-9","article-title":"Citalopram-induced Raynaud's phenomenon","volume":"27","author":"Peir\u00f3","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reuma.2012.02.006_bib0300","first-page":"2257","article-title":"Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study","volume":"28","author":"Sambo","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2012.02.006_bib0305","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/039463200501800420","article-title":"Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynaud's phenomenon","volume":"18","author":"Salsano","year":"2005","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.reuma.2012.02.006_bib0310","first-page":"1801","article-title":"Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers","volume":"35","author":"Abou-Raya","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2012.02.006_bib0315","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jhsa.2008.11.026","article-title":"Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon","volume":"34A","author":"Fregene","year":"2009","journal-title":"J Hand Surg"},{"issue":"3 Suppl 54","key":"10.1016\/j.reuma.2012.02.006_bib0320","first-page":"51","article-title":"Vitamin E gel reduces time of healing of digital ulcers in systemic sclerosis","volume":"27","author":"Fiori","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reuma.2012.02.006_bib0325","first-page":"1788","article-title":"A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia","volume":"30","author":"Kotsis","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2012.02.006_bib0330","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jvs.2011.01.069","article-title":"Thoracic sympathectomy for digital ischemia: a summary of evidence","volume":"54","author":"Coveliers","year":"2011","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.reuma.2012.02.006_bib0335","first-page":"455","article-title":"Calcinosis cutis occurring in association with autoimmune connective tissue disease. The Mayo Clinic Experience with 78 patients, 1996-2009","volume":"184","author":"Balin","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.reuma.2012.02.006_bib0340","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.semarthrit.2011.11.007","article-title":"Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature","volume":"41","author":"Daoussis","year":"2012","journal-title":"Semin Arthritis Rheum"}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X12000903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X12000903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T07:20:29Z","timestamp":1564644029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X12000903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S1699258X12000903"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2012.02.006","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}